We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





New Rapid COVID-19 Test Beats ELISA Method in Identifying SARS-CoV-2 Antibodies in Blood Within Just 12 Minutes

By LabMedica International staff writers
Posted on 10 Feb 2021
A new rapid COVID-19 test to detect coronavirus antibodies beats the enzyme linked immunosorbent assay (ELISA) method in delivering results within just 12 minutes, marking a milestone in the development of immunological diagnostics.

An international research team involving the University of Paraná (Paraná, Brazil) and the University of Tübingen (Tübingen, Germany) has developed the new rapid test that can reliably identify COVID-19 antibodies in the blood within minutes. More...
The new process is based on a simple measuring principle, making it easy to carry out without expensive instruments and is therefore, suitable for use at mobile testing centers or by laboratories in less economically developed regions. The new diagnostic method is also far faster than the ELISA procedure, which for decades has been seen as the gold standard for laboratory diagnosis of antibodies.

The new test is based on magnetic nanoparticles that are coated with viral antigens. To conduct the test, blood serum or blood is applied to the test surface. After roughly two minutes, the nanoparticles are washed and treated with a developer reagent. If the blood sample displays antibodies to coronavirus, a color change occurs. While the traditional ELISA test produces results after about three hours, study results show that the new method only takes 12 minutes. Positive and negative results can be established simply with the naked eye, and by using additional instruments, such as a microplate reader, the precision of the test can be further increased. The total response time is 15 times shorter than that of the classic ELISA test, which means that hundreds of samples can be tested in just a few hours.

In addition, the study shows that the new technology can also be applied to the serological diagnosis of other diseases. There are no reports in research literature on an immunology test for COVID-19 that delivers data as quickly, as precisely and above all as cheaply. The researchers believe that it will be possible to offer the new test at a comparable price to the ELISA test in future.

“Only a small sample is needed for the test: a single drop that contains two microliters of serum is sufficient,” said the study’s lead author, Professor Luciano F. Huergo from the University of Paraná: “It’s also possible to use whole blood, in other words the separation of soluble blood components that is normally necessary can be omitted. It isn’t absolutely necessary to have a fully-equipped laboratory or use special equipment to carry it out.”

“Another advantage over the ELISA procedure is that the color result of our new procedure is directly proportional to the concentration of antibodies,” added Huergo. “In other words, the new method delivers data on the quantity of antibodies and not just whether any are present.”

Related Links:
University of Paraná
University of Tübingen



Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Biodesix is developing a radiomics-based lung nodule risk assessment test to complement its Nodify Lung portfolio (Photo courtesy of Biodesix)

Multimodal Platform to Combine Blood and Imaging Biomarkers for Lung Nodule Assessment

Lung nodules are commonly detected during chest imaging and require careful risk assessment to determine whether follow-up imaging, additional testing, or biopsy is needed. With millions of patients evaluated... Read more

Molecular Diagnostics

view channel
Image

GeneDx Presents Evidence for Wider Clinical Use of Genomic Sequencing at ASHG 2026

GeneDx (Gaithersburg, MD, USA) is presenting 27 scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, taking place October 20–24 in Montreal, Canada.... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.